EUVIMEDEUVIMED entdecken
Metaanalyse

The Global Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among Patients With Type 2 Diabetes

Zobair M Younossi, Pegah Golabi, Jillian Kallman Price, Soroor Owrangi, Nagashree Gundu-Rao, Romona Satchi, James M Paik

Clinical Gastroenterology and Hepatology · 2024-10 · 22 (10) · 1999-2010.e8

DOI: 10.1016/j.cgh.2024.03.006 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Clinical Gastroenterology and Hepatology, 2024-10. Verfasst von Zobair M Younossi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Beatty Liver and Obesity Research Program, Inova Health System, Falls Church, Virginia; Center for Liver Disease, Department of Medicine, Inova Fairf…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Global Health, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 438-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: Inova Health System.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: Nonalcoholic fatty liver disease (NAFLD), now known as metabolic dysfunction associated steatotic liver disease (MASLD), is closely associated with type 2 diabetes (T2D). Our aim was to estimate the most recent global prevalence of NAFLD/MASLD, nonalcoholic steatohepatitis (NASH), now known as metabolic dysfunction associated steatohepatitis (MASH), advanced fibrosis, and mortality among patients with T2D. METHODS: We systematically searched PubMed and Ovid MEDLINE for terms including NAFLD, NASH, and T2D published in 1990-2023 according to PRISMA. The meta-analysis was conducted using a random-effects model. Assessment of bias risk used the Joanna Briggs Institute appraisal tool. RESULTS: From 3134 studies included in the initial search, 123 studies (N = 2,224,144 patients with T2D) were eligible. Another 12 studies (N = 2733 T2D patients with liver biopsy) were eligible for histologic assessments. The global pooled prevalence of NAFLD/MASLD among patients with T2D was 65.33% (95% confidence interval, 62.35%-68.18%). This prevalence increased from 55.86% (42.38%-68.53%) in 1990-2004 to 68.81% (63.41%-73.74%) in 2016-2021 (P = .073). The highest NAFLD/MASLD prevalence among T2D patients was observed in Eastern Europe (80.62%, 75.72%-84.73%), followed by the Middle East (71.24%, 62.22%-78.84%), and was lowest in Africa (53.10%, 26.05%-78.44%). Among patients with liver biopsy data, the global pooled prevalence of NASH/MASH, significant fibrosis, and advanced fibrosis was 66.44% (56.61%-75.02%), 40.78% (24.24%-59.70%), and 15.49% (6.99%-30.99%), respectively. The pooled all-cause mortality was 16.79 per 1000 person-years (PY) (10.64-26.40), 4.19 per 1000 PY (1.34-7.05) for cardiac-specific mortality; 6.10 per 1000 PY (0.78-4.88) for extrahepatic cancer-specific mortality; and 2.15 per 1000 PY (0.00-2.21) for liver-specific mortality. CONCLUSIONS: The prevalence of NAFLD/MASLD among T2D is high and growing. The majority of NAFLD/MASLD patients with T2D have NASH/MASH, and a significant proportion have advanced fibrosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Global HealthNon-alcoholic Fatty Liver DiseaseHumansPrevalence

Stichwörter der Autor:innen

MASHMASLDNAFLDNASHSteatotic Liver DiseaseT2D

Autor:innen und Institutionen

  • Beatty Liver and Obesity Research Program, Inova Health System, Falls Church, Virginia; Center for Liver Disease, Department of Medicine, Inova Fairfax Medical Campus, Falls Church, Virginia; The Global NASH Council, Wa…
  • Beatty Liver and Obesity Research Program, Inova Health System, Falls Church, Virginia; Center for Liver Disease, Department of Medicine, Inova Fairfax Medical Campus, Falls Church, Virginia.
  • Beatty Liver and Obesity Research Program, Inova Health System, Falls Church, Virginia.
  • The Global NASH Council, Washington, District of Columbia.

Förderung

  • Inova Health System

Zitieren

APA

Younossi, Z. M., Golabi, P., Price, J. K., Owrangi, S., Gundu-Rao, N., Satchi, R., & Paik, J. M. (2024). The Global Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among Patients With Type 2 Diabetes. Clinical Gastroenterology and Hepatology, 22(10), 1999-2010.e8. https://doi.org/10.1016/j.cgh.2024.03.006

Vancouver

Younossi ZM, Golabi P, Price JK, Owrangi S, Gundu-Rao N, Satchi R, et al. The Global Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among Patients With Type 2 Diabetes. Clinical Gastroenterology and Hepatology. 2024;22(10):1999-2010.e8. doi:10.1016/j.cgh.2024.03.006

BibTeX
@article{Younossi2024,
  author = {Younossi, Zobair M and Golabi, Pegah and Price, Jillian Kallman and Owrangi, Soroor and Gundu-Rao, Nagashree and Satchi, Romona and Paik, James M},
  title = {The Global Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among Patients With Type 2 Diabetes},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2024},
  volume = {22},
  number = {10},
  pages = {1999--2010.e8},
  doi = {10.1016/j.cgh.2024.03.006}
}
Kostenlos starten →